RankAlpha logo
Back to Rankings

QURE

uniQureF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-08-06
View Chart
Current thesis
The company source supports a still-constructive monitoring thesis: AMT-130 retains an active regulatory path, the UK filing remains targeted for Q3 2026, AMT-260 has a dated June catalyst, and cash runway into 2H29 reduces immediate financing pressure [#8-K-2026-05-05].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
AMT-191 has dose-limiting toxicity concerns: additional mid- and high-dose dosing remains paused pending evaluation of asymptomatic Grade 3 liver enzyme elevations in two patients [#8-K-2026-05-05].
Momentum
98
Value
41
Sentiment
14
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $36.00 · Bear $20.00
Data freshness
Prices
As of 2026-08-06
Fundamentals
As of 2026-08-06 • Vendor: Data Vendor v1
Scores
As of 2026-08-06 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-08-06
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $68.00
Why
Momentum98 · Δ7d +2.8
Value41 · Δ7d -0.0
Sentiment14 · Δ7d +0.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
98
10% active weight
Current posture
7d trendImproving
Δ7d
+2.8
Δ21d
+0.1
Value
41
40% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
14
49% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
-2.8
Why this grade

Composite grade F. Momentum 98.5 / Value 41.0 / Sentiment 13.8

Fundamentals (TTM)
As of 2026-08-06
Market Cap
$3.15B
Beta
0.67
Shares Out
69.37M
P/E (TTM) · Derived
-13.1
P/S (TTM)
89.50
P/FCF (TTM) · Derived
-15.28
Rev YoY
+127.3%
EPS YoY
+3.8%
Gross Margin
+17.7%
Op Margin
-1143.2%
Net Debt
-$85.95M
Current Ratio
10.40
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology